SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
Entitled, "Inhibition of erlotinib resistance on HER-family tyrosinekinases by combination with MP-470, a multi-targeted TK inhibitor in prostateand breast cancer," the poster highlights data indicating that the combinationof MP-470 and erlotinib inhibits the binding of the p85 subunit of PI3K, andhas a greater impact than either agent alone in reducing phosphorylation ofAkt, ERK1/2, EGFR/HER1, HER2/Neu, and HER3.
"These data build upon previous results showing that MP-470 exhibitsanti-tumor activity in breast and prostate cancer cells," said Dr. DavidBearss, SuperGen's Vice President and Chief Scientist. "The fact that MP-470in combination with erlotinib effectively suppressed the HER pathway suggeststhat concurrent administration of both compounds could represent a newtreatment for prostate and breast cancers. We will continue to explore thissynergy as we develop further MP-470."
Copies of the 2008 AACR Annual Meeting poster presentations will beavailable in the pipeline section of SuperGen's Web site www.supergen.com.
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements are typically preceded by words such as "believes," "expects,""anticipates," "intends," "will," "may," "should," or similar expressions.These forward-looking statements are not guarantees of future performance andinvolve a number of risks and uncertainties that may cause actual results todiffer materially from the results discussed in these statements. Factorsthat might cause the company's results to differ materially from thoseexpressed or implied by such forward-looking statements include, but are notlimited to, the ability to discover, develop and move target compounds intoclinical development and other risks and uncertainties detailed from time totime in the company's filings with the Securities and Exchange Commissionincluding its most recently filed Form 10-Q and 10-K. SuperGen, Inc.undertakes no duty to update any of these forward-looking statements toconform them to actual results.Contacts Timothy L. Enns Mary M. Vegh SuperGen, Inc. SuperGen, Inc. SVP, Corporate Communications & Business Manager, Investor Development Relations Tel: (925) 560-0100 Tel: (925) 560-2845 E-mail: email@example.com E-mail: firstname.lastname@example.org
SOURCE SuperGen Inc.
You May Also Like